Dr. Marc C. Gittelman, MD

Dr. Gittelman practices at Uromedix in Cape Coral, Florida.

Dr. Gittelman's NPI, 1174587604, was assigned on April 13, 2006. Dr. Gittelman graduated from Icahn School Of Medicine At Mount Sinai in 1983. Dr. Gittelman holds Florida license ME53015.

Dr. Gittelman's primary practice is Uromedix, at 1419 SE 8th Ter, Cape Coral, FL 33990 in Lee County. The practice phone is (954) 987-3010.

Dr. Gittelman's primary practice is Uromedix in Cape Coral, Florida. The medical group on file is GenesisCare. Dmand AI also links Dr. Gittelman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gittelman practices. Vendor and product names are available with a free account.

Urology is Dr. Gittelman's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Gittelman is board certified in urology by the American Board of Urology. Dr. Gittelman is licensed in Florida.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney cysts, kidney stone disease, testicular dysfunction, urinary endoscopy and UTI among the conditions Dr. Gittelman treats.

CMS data shows 728 Medicare services from Dr. Gittelman across 7 procedure codes in 2024, for 188 Medicare patients. Medicare paid $37,904 for them. Every service was in an office.

CMS counts 188 Medicare patients who saw Dr. Gittelman in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gittelman's median patient age at 68, with 15% women.

In 2024, Dr. Gittelman wrote 1,028 Medicare Part D claims for 404 patients. 83% of them were for generic drugs. CMS names the drug for 937 of them, across 19 drugs with 11 or more claims each, at $111,725 in total drug cost. In 2023, CMS named 527 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Gittelman for performance year 2024, reported individually. Dr. Gittelman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 45 papers to Dr. Gittelman, published from 2006 to 2022. 2016 was the busiest year, with 4. The most frequent topics are Double-Blind Method, Imidazoles and Sulfones. Dr. Gittelman has published most often in J Urol. Dr. Gittelman's most frequent co-authors are Claus G. Roehrborn, MD, Jed C. Kaminetsky, MD and Christopher H. Cantrill, MD.

Dmand AI links Dr. Gittelman to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Prostatic Hyperplasia, Nocturia and Prostatic Diseases. Vantia Ltd sponsors the most, 2.

CMS Open Payments shows 284 general payments to Dr. Gittelman from 42 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 64% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $23,155.

Dmand AI lists 1 award for Dr. Gittelman.

Dr. Gittelman graduated from Icahn School Of Medicine At Mount Sinai in 1983. Dr. Gittelman is a member of ACS, AMA, AUA, International Society for the Study of Women's Sexual Health, International Society of Sexual Medicine and Sexual Medicine Society of North America, Inc.

Dr. Gittelman is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.